We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





KaiMi Biotech Highlights First of Its Kind Color-Changing Swabs

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: QiDix color-changing swabs (Photo courtesy of KaiMi Biotech)
Image: QiDix color-changing swabs (Photo courtesy of KaiMi Biotech)

KaiMi Biotech (Jiangsu, China) is highlighting its innovative Unow multiplexing drug tests and first-of-its-kind QiDix color-changing swabs at MEDICA 2023.

KaiMi Biotech has launched a series of breakthrough Unow multiplexing drug tests based on its proprietary user-friendly Unow technology platform. These innovative drug tests offer several unprecedented advantages over existing drug tests available in the market to meet the long unmet needs of users. The tests need only a small quantity of saliva sample (80 ml) and a short sampling time (2s) to provide user convenience. A color-appearing indicator tells users if enough saliva has been collected to give them confidence and prevent test inconsistency as a result of sampling errors.

The Unow multiplexing drug tests can be run by a single hand with fewer steps than existing commercial tests and the results can be obtained in 5-10 minutes. Integrated running buffers in the test devices eliminate direct user contact with liquid diluent and reduce potential contamination. The US FDA-approved and CE-marked tests offer excellent detection sensitivity for all the common drugs of abuse that meets the standard cutoffs for most regions around the world. The tests offer great flexibility for customization for detecting different combinations of drugs in a single device to meet the customer’s specific needs.

At MEDICA 2023, KaiMi is also presenting its flagship product, the QiDix color-changing swabs. These swabs are immobilized with a proprietary color indicator to help users ensure that enough samples have been collected. The US FDA-approved QiDix swabs are particularly useful for collecting samples for babies and kids, or patients who have challenges collecting samples by themselves. The indicator can be triggered by body fluids such as saliva, nasal secretion, sweat, tears, and urine, but not by water. The color change will not fade once triggered and the color indicators consist of only safe food-grade ingredients. A number of types of QiDix swabs are available, ranging from flocked swabs, woven swabs, and cotton swabs.

Related Links:
KaiMi Biotech

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.